申请人:PACIFIC ARROW LIMITED
公开号:US10590163B2
公开(公告)日:2020-03-17
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases. The compounds are attached with angeloyl, acetyl, tigloyl, senecioyl, Crotonoyl, 3,3-Dimethylartyloyl, Cinnamoyl, Pentenoyl, Hexanoyl, benzoyl, Ethylbutyryl, benzoyl, dibenzoyl, alkanoyl, alkenoyl, benzoyl alkyl substituted alkanoyl, ethanoyl, propanoyl, propenoyl, butanoyl, butenoyl, pentanoyl, hexenoyl, heptanoyl, heptenoyl, octanoyl, octenoyl, nonanoyl, nonenoyl, decanoyl, decenoyl, propionyl, 2-propenoyl, 2-butenoyl, Isobutyryl, 2-methylpropanoyl, 2-ethylbutyryl, ethylbutanoyl, 2-ethylbutanoyl, butyryl, (E)-2,3-Dimethylacryloyl, (E)-2-Methylcrotonoyl, 3-cis-Methyl-methacryloyl, 3-Methyl-2-butenoyl, 3-Methylcrotonoyl, 4-Pentenoyl, (2E)-2-pentenoyl, Caproyl, 5-Hexenoyl, Capryloyl, Lauroyl, Dodecanoyl, Myristoyl, Tetradecanoyl, Oleoyl, O—C(2-18) Acyl.
本发明提供了一种合成新活性化合物的方法,用于包括癌症治疗在内的药物用途,其中癌症包括乳腺癌、白细胞癌、肝癌、卵巢癌、膀胱癌、前列腺癌、皮肤癌、骨癌、脑癌、白血病、肺癌、结肠癌、中枢神经系统癌、黑色素瘤、肾癌、宫颈癌、食道癌、睾丸癌、脾癌、肾癌、淋巴癌、胰腺癌、胃癌和甲状腺癌。本发明是一种抗粘附疗法,利用化合物作为粘附蛋白和血管生成素的介质或抑制剂。它能抑制过量粘附,抑制细胞附着。它能调节血管生成。该化合物还可用作细胞粘附受体、细胞循环、细胞移动和炎症性疾病的介质。烷酰基、苯甲酰基、烷基取代的烷酰基、乙酰基、丙酰基、丙烯酰基、丁酰基、丁烯酰基、戊酰基、己酰基、庚酰基、庚烯酰基、辛酰基、辛烯酰基、壬酰基、壬烯酰基、癸酰基、癸酰基、丙酰基、2-丙烯酰基、2-丁烯酰基、异丁酰基、2-甲基丙酰基、2-乙基丁酰基、乙基丁酰基、2-乙基丁酰基、丁酰基、(E)-2,3-二甲基丙烯酰基、(E)-2-甲基巴豆酰基、3-顺式-甲基甲基丙烯酰、3-甲基-2-丁烯酰、3-甲基巴豆酰、4-戊烯酰、(2E)-2-戊烯酰、己酰、5-己烯酰、辛酰、月桂酰、十二碳酰、肉豆蔻酰、十四碳酰、油酰、O-C(2-18)酰。